QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 10/3/300    most recent 15228517-2008-005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kesari, S. Articles by Wen, P. Y. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

Dana-Farber/Brigham and Women's Cancer Center, Center for Neuro-Oncology, Boston, MA (S.K., D.C.G., L.D., N.R., P.M.B., J.D., A.C., P.Y.W.); Departments of Neurology (S.K., J.D., P.Y.W.), Pathology (J.A.L., K.L.L.), Radiation Oncology (N.R.), and Neurosurgery (P.M.B.), Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA (S.K., J.W.H., A.M., T.T.B., J.A.L., K.L.L., N.R., P.M.B., J.D., J.F., M.K., P.Y.W.); Neuro-Oncology Center, University of Virginia, Charlottesville, VA (D.S.); Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA (J.W.H., T.T.B.); Massachusetts General Hospital, Boston, MA (A.M.); Albany Medical Center, Albany, NY (S.W.); Division of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital, Boston, MA (A.L., M.K.); Department of Surgery, Vascular Biology Program, Children's Hospital, Boston, MA (A.L., J.F., M.K.); USA

Address correspondence to Patrick Y. Wen, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, 44 Binney St., SW430D, Boston, MA 02115, USA (pwen{at}partners.org).

We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma. Patients who had stable disease following standard radiation therapy received temozolomide for 5 days in 28-day cycles, in combination with daily thalidomide and celecoxib. Patients were treated until tumor progression or development of unacceptable toxicity. Four-month progression-free survival (PFS) from study enrollment was the primary end point, and overall survival (OS) was the secondary end point. In addition, we sought to correlate response with O⁶-methylguanine-DNA methyltransferase promoter methylation status and serum levels of angiogenic peptides. Fifty patients with glioblastoma were enrolled (18 women, 32 men). Median age was 54 years (range, 29–78) and median KPS score was 90 (range, 70–100). From study enrollment, median PFS was 5.9 months (95% confidence interval [CI]: 4.2–8.0) and 4-month PFS was 63% (95% CI: 46%–75%). Median OS was 12.6 months (95% CI: 8.5–16.4) and 1-year OS was 47%. Of the 47 patients evaluable for best response, none had a complete response, five (11%) had partial response, four (9%) had minor response, 22 (47%) had stable disease, and 16 (34%) had progressive disease. Analysis of serial serum samples obtained from 47 patients for four angiogenic peptides failed to show a significant correlation with response or survival for three of the peptides; higher vascular endothelial growth factor levels showed a trend toward correlation with decreased OS (p = 0.07) and PFS (p = 0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment.

Key Words: angiogenesis • chemotherapy • clinical trial • glioblastoma

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?